Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-40.48%
0%
-40.48%
6 Months
-44.44%
0%
-44.44%
1 Year
-19.35%
0%
-19.35%
2 Years
-54.55%
0%
-54.55%
3 Years
-75.0%
0%
-75.0%
4 Years
-90.38%
0%
-90.38%
5 Years
-82.76%
0%
-82.76%
DXS International Plc for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
1.13%
EBIT Growth (5y)
-15.14%
EBIT to Interest (avg)
-0.97
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
1.54
Tax Ratio
2.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.47%
ROE (avg)
5.05%
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
NA
EV to EBIT
0.02
EV to EBITDA
0.10
EV to Capital Employed
-0.10
EV to Sales
-0.03
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-461.60%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Apr'23
Apr'23
Apr'22
Change(%)
Net Sales
3.40
3.30
3.03%
Operating Profit (PBDIT) excl Other Income
0.60
0.60
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
0.20
0.20
Operating Profit Margin (Excl OI)
-20.60%
-18.50%
-0.21%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2023 is 3.03% vs -8.33% in Apr 2022
Consolidated Net Profit
YoY Growth in year ended Apr 2023 is 0.00% vs -60.00% in Apr 2022
About DXS International Plc 
DXS International Plc
Software Products
DXS International PLC is engaged in the development and distribution of clinical decision support to general practitioners, nurses and retail pharmacies in the United Kingdom and South Africa. The Company is also engaged in licensing its services to various clinical commissioning groups (CCGs); selling of e-detailing opportunities to the pharmaceutical industry and the United Kingdom care sector, and licensing of DXS technology to healthcare publishers. The Company's products include DXS Point-of-Care (DXS PoC), which is a clinical decision support system (CDSS); DXS Best Pathway, which supports the implementation of CCG designated clinical guidelines and protocols; DXS Best Script, which is a medicine database; DXS Best Triage, which manages CCG referral triaging requirements, and DXS Directory-of-Services (DoS), which provides general practitioners (GPs) and nurses with a directory of available referral services in the work flow.
Company Coordinates 
Company Details
Wrecclesham House, Wrecclesham Road , FARNHAM None : GU10 4PS
Registrar Details






